Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Methods and effects of improved conventional insulin treatment in labile insulin-dependent diabetes (IDDM).

Menzel R, Brunstein U, Conde N, Bombor H, Albrecht G, Jutzi E.

Exp Clin Endocrinol. 1984 Apr;83(2):152-60.

PMID:
6373317
[PubMed - indexed for MEDLINE]
2.

[Insulin therapy of Type I diabetes].

Berger W.

Ther Umsch. 1996 Dec;53(12):902-13. German.

PMID:
9036568
[PubMed - indexed for MEDLINE]
3.

Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.

Pampanelli S, Torlone E, Ialli C, Del Sindaco P, Ciofetta M, Lepore M, Bartocci L, Brunetti P, Bolli GB.

Diabetes Care. 1995 Nov;18(11):1452-9.

PMID:
8722069
[PubMed - indexed for MEDLINE]
4.

Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.

Roach P, Bai S, Charbonnel B, Consoli A, Taboga C, Tiengo A, Bolli G; High Mix Study Group.

Clin Ther. 2004 Apr;26(4):502-10.

PMID:
15189747
[PubMed - indexed for MEDLINE]
5.

The KID Study. III: Impact of inpatient rehabilitation on the metabolic control of type I and type II diabetics--a one-year follow-up.

Haupt E, Herrmann R, Benecke-Timp A, Vogel H, Hilgenfeldt J, Haupt A, Walter C.

Exp Clin Endocrinol Diabetes. 1996;104(6):420-30.

PMID:
9021342
[PubMed - indexed for MEDLINE]
6.

Meal composition is a determinant of lispro-induced hypoglycemia in IDDM.

Burge MR, Castillo KR, Schade DS.

Diabetes Care. 1997 Feb;20(2):152-5.

PMID:
9118763
[PubMed - indexed for MEDLINE]
7.

Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.

Genuth S.

Ann Intern Med. 1996 Jan 1;124(1 Pt 2):104-9.

PMID:
8554200
[PubMed - indexed for MEDLINE]
8.

Insulin lispro: its role in the treatment of diabetes mellitus.

Campbell RK, Campbell LK, White JR.

Ann Pharmacother. 1996 Nov;30(11):1263-71. Review.

PMID:
8913409
[PubMed - indexed for MEDLINE]
9.
10.

Comparison of insulin lispro with regular human insulin for the treatment of type 1 diabetes in adolescents.

Holcombe JH, Zalani S, Arora VK, Mast CJ; Lispro in Adolescents Study Group.

Clin Ther. 2002 Apr;24(4):629-38.

PMID:
12017407
[PubMed - indexed for MEDLINE]
11.

Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.

Pfützner A, Küstner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, Schatz H, Beyer J.

Exp Clin Endocrinol Diabetes. 1996;104(1):25-30.

PMID:
8750567
[PubMed - indexed for MEDLINE]
12.

Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM.

Fanelli C, Pampanelli S, Epifano L, Rambotti AM, Di Vincenzo A, Modarelli F, Ciofetta M, Lepore M, Annibale B, Torlone E, et al.

Diabetologia. 1994 Dec;37(12):1265-76. Erratum in: Diabetologia 1995 Feb;38(2):254.

PMID:
7895957
[PubMed - indexed for MEDLINE]
13.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
[PubMed - indexed for MEDLINE]
14.

Long-term improvement in metabolic control of unstable type I diabetes by s.c. insulin injection patterns based on the dose profiles required by bed-side artificial beta-cell.

Bombor H, Bruns W, Ratzmann KP, Jutzi E, Albrecht G, Michaelis D, Fischer U.

Exp Clin Endocrinol. 1984 Apr;83(2):143-51.

PMID:
6373316
[PubMed - indexed for MEDLINE]
15.

Improvement in blunted glucagon response to insulin-induced hypoglycemia by strict glycemic control in diabetics.

Katsura M, Kawamori R, Yamasaki Y, Iwama N, Kubota M, Goriya Y, Kajimoto Y, Shichiri M, Kamada T.

Diabetes Res Clin Pract. 1993 May;20(2):93-100.

PMID:
8375272
[PubMed - indexed for MEDLINE]
16.

Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.

Kabadi UM.

Clin Drug Investig. 2008;28(11):697-701.

PMID:
18840012
[PubMed - indexed for MEDLINE]
17.

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

Clin Ther. 2004 May;26(5):724-36.

PMID:
15220016
[PubMed - indexed for MEDLINE]
18.

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA.

Diabetes Care. 2000 May;23(5):639-43.

PMID:
10834423
[PubMed - indexed for MEDLINE]
Free Article
19.

A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.

Jacober SJ, Scism-Bacon JL, Zagar AJ.

Diabetes Obes Metab. 2006 Jul;8(4):448-55.

PMID:
16776752
[PubMed - indexed for MEDLINE]
20.

Insulin glargine: a systematic review of a long-acting insulin analogue.

Wang F, Carabino JM, Vergara CM.

Clin Ther. 2003 Jun;25(6):1541-77, discussion 1539-40. Review.

PMID:
12860485
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk